References
- Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H (2004). The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res, 24(3b), 1941-6.
- Bremnes RM, Sundstrom S, Aasebo U, et al (2003). The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year followup. Lung Cancer, 39, 303-13. https://doi.org/10.1016/S0169-5002(02)00508-1
- Chua YJ, Steer C, Yip D (2004). Recent advances in management of small-cell lung cancer. Cancer Treat Rev, 30, 521-43. https://doi.org/10.1016/j.ctrv.2004.06.003
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Fizazi K, Cojean I, Pignon JP, et al (1998). Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer, 82, 1049-55. https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1049::AID-CNCR6>3.0.CO;2-9
- Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jeremic B, Shibamoto Y, Nikolic N, et al (1999). Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol, 17, 2092-9.
- Khuder SA (2001). Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer, 31, 139-48. https://doi.org/10.1016/S0169-5002(00)00181-1
- Li J, Dai CH, Chen P, et al (2010). Survival and prognostic factors in small cell lung cancer. Med Oncol, 27, 73-81. https://doi.org/10.1007/s12032-009-9174-3
- Micke P, Faldum A, Metz T, et al (2002). Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer, 37, 271-6. https://doi.org/10.1016/S0169-5002(02)00072-7
- Neal JW, Gubens MA, Wakelee HA (2011). Current management of small cell lung cancer. Clin Chest Med, 32, 853-63. https://doi.org/10.1016/j.ccm.2011.07.002
- O'Brien ME, Ciuleanu TE, Tsekov H, et al (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol, 24, 5441-7. https://doi.org/10.1200/JCO.2006.06.5821
- Ou SH, Ziogas A, Zell JA (2009). Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol, 4, 37-43. https://doi.org/10.1097/JTO.0b013e31819140fb
- Paesmans M, Sculier JP, Lecomte J, et al (2000). Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer, 89, 523-33. https://doi.org/10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6
- Singh S, Parulekar W, Murray N, et al (2005). Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol, 23, 850-6. https://doi.org/10.1200/JCO.2005.03.171
- Slotman B, Faivre-Finn C, Kramer G, et al (2007). Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 357, 664-72. https://doi.org/10.1056/NEJMoa071780
- Sorensen M, Pijls-Johannesma M, Felip E (2010). Smallcell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 5, v120-5.
- Ustuner Z, Saip P, Yasasever V, et al (2008). Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol, 25, 394-9. https://doi.org/10.1007/s12032-008-9052-4
- Yang X, Wang D, Yang Z, et al (2011). CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys, 59, 113-9. https://doi.org/10.1007/s12013-010-9121-0
Cited by
- Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4205
- Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution in Turkey vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6263
- Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5285
- Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer vol.36, pp.10, 2015, https://doi.org/10.1007/s13277-015-3467-2
- Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer vol.19, pp.7, 2017, https://doi.org/10.1007/s12094-017-1617-2
- miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway vol.38, pp.3, 2017, https://doi.org/10.3892/or.2017.5808